Angiotensin News and Research RSS Feed - Angiotensin News and Research

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
Older people could be at greater risk for negative consequences of consuming high-salt diet

Older people could be at greater risk for negative consequences of consuming high-salt diet

Aging is associated with a number of changes that cause the body to function less efficiently, including the way the body controls water and sodium levels. Research has shown that as humans and animals age, they are less able to regulate sodium and water retention, urine concentration and thirst compared to their younger counterparts. [More]
FDA-approved blood pressure drug reduces cell damage linked to Alzheimer's disease

FDA-approved blood pressure drug reduces cell damage linked to Alzheimer's disease

In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer's disease, say researchers at Georgetown University Medical Center and the National Institutes of Health. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers. [More]
Case Western scientist to lead a pair of studies to develop more effective treatment for CF

Case Western scientist to lead a pair of studies to develop more effective treatment for CF

A scientist at Case Western Reserve University Frances Payne Bolton School of Nursing will lead a pair of studies to develop more effective treatment for symptoms of cystic fibrosis (CF), a life-threatening genetic disease that causes persistent lung infections and progressively limits the ability to breathe. [More]
Doctors in Mexico show benefits of healthy diet, exercise in heart failure patients

Doctors in Mexico show benefits of healthy diet, exercise in heart failure patients

Doctors in Mexico have shown the benefits of a healthy diet and exercise in patients with heart failure, in research presented at the Mexican Congress of Cardiology 2015. [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
Circulating protein predicts risk of chronic kidney disease

Circulating protein predicts risk of chronic kidney disease

Make room, cholesterol. A new disease marker is entering the medical lexicon: suPAR, or soluble urokinase-type plasminogen activator receptor. [More]
Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

New research published in The Lancet shows that the use of vital life-saving generic (and supposedly inexpensive) medicines for prevention in people with existing heart disease is poor worldwide. In low-income and middle-income countries these medicines are not widely available and, when available, can often be unaffordable. In rich countries, although such medicines are both available and affordable, 35% to 50% of patients who have heart disease or a previous stroke still do not receive them. [More]
Radical shift required in use of heart medicine worldwide

Radical shift required in use of heart medicine worldwide

Many people in the world who need essential heart medicine do not get it, even in rich countries, says new research published today in the medical journal The Lancet. [More]
Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high. [More]
Cardiac monitoring predicts survival in patients with Friedreich ataxia

Cardiac monitoring predicts survival in patients with Friedreich ataxia

Researchers confirm the need for cardiac follow-up in patients with Friedreich ataxia, with particular focus on left ventricular ejection fraction as a predictor of worse prognosis. [More]
High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

While high levels of the satiety hormone leptin don't help obese individuals lose weight, they do appear to directly contribute to their cardiovascular disease, researchers report. [More]
Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients. [More]
Common hypertension drugs worsen cardiovascular outcomes in hypertensive African Americans

Common hypertension drugs worsen cardiovascular outcomes in hypertensive African Americans

Drugs commonly used to treat high blood pressure, and prevent heart attacks and strokes, are associated with significantly worse cardiovascular outcomes in hypertensive African Americans compared to whites, according to a new comparative effectiveness research study led by researchers in the Department of Population Health at NYU Langone Medical Center. [More]
UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern Medical Center has joined an international clinical trial studying whether a drug traditionally used to treat gout can help prevent kidney damage in patients with Type 1 diabetes. [More]
Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical Limited today announced the first patient had been enrolled in a Phase II study of DMX-200, an innovative new treatment that combines two different drugs to treat chronic kidney disease. [More]
Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal. [More]
Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA. [More]
Gene linked to sudden cardiac death in general population identified using ICD monitoring

Gene linked to sudden cardiac death in general population identified using ICD monitoring

A gene associated with sudden cardiac death in the general population has been identified using implantable cardioverter defibrillator (ICD) monitoring in research presented for the first time at ESC Congress today. [More]
Advertisement
Advertisement